Biotech Business - February 28, 2024
NextCell Pharma updates growth strategy
The company’s strategic changes include a staff reduction, Cellaviva becoming a wholly owned subsidiary and the GMP facility will have new sources of revenue. NextCell develops the cell therapy drug ProTrans for the treatment of type 1 diabetes. ProTrans is now being evaluated in a clinical trial. In addition, a five year follow-up of previous […]
Business article - February 26, 2024
InDex discontinues development of cobitolimod and provides future update
InDex Pharmaceuticals will discontinue development of their drug candidate cobitolimod. Thorough analysis of the data from Induction Study 1 of the phase III program CONCLUDE has not provided any results justifying continued development, states the company. “We are very disappointed that we cannot detect a treatment benefit of cobitolimod compared to placebo, and that we […]
Agreement - February 26, 2024
Kancera resolves on a right issue and enters license agreement
The board of directors of Kancera has resolved on a new share issue with preferential rights for the company’s existing shareholders of approximately SEK 121.9 million. The objective of the Rights Issue is to secure resources to advance the company’s development program, consisting of the candidate drugs KAND567 and KAND145, to start of new clinical […]
Biotech Business - February 14, 2024
TILT Biotherapeutics awarded USD 2 million grant
TILT Biotherapeutics has been selected by the U.S. Department of Defense (DOD) to receive a grant for a three-year project on treatment for ovarian cancer using the company’s TILT-123 asset. The aims of the DOD funded project are to assess safety, signs of efficacy of TILT-123 in combination with pembrolizumab in platinum-resistant/refractory ovarian cancer patients […]
Biotech Business - February 13, 2024
Genovis receives USD 1 million in milestone compensation
The milestone compensation is related to achieved development goals for the Xork enzyme that Genovis has licensed for therapeutic applications, primarily as a potential pre-treatment in gene therapy but also for autoimmune diseases. Xork was discovered in a subset of streptococci that do not infect humans and the preclinical data generated to date clearly show […]
Financing - February 12, 2024
“There will be even further focus on longevity and the microbiome”
Nordic Life Science asked Casper Breum, Managing Partner, Sound Bioventures, about his predictions for 2024, including market trends, financing opportunities for SMEs and business strategy advice. What do you predict will be the dominant market trend within life sciences this year? “A continued and increased focus on cost and value for money in healthcare. The […]
